Perfect Medical Industry Co., Ltd.

Perfect Medical Industry Co., Ltd.

TTPEX:6543
16.70
TWD
-0.10
(-0.60%)
1.04BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
14.5
14.92
15.77
18.57
16.8
14.43
15.41
14.49
13.71
- -
Basic EPS, GAAP
0.58
0.97
0.85
2.31
0.9
0.3
0.84
1.74
0.95
- -
Free Cash Flow per Basic Share
-1.35
-0.15
1.09
-0.6
-2.3
1.13
1.75
0.88
-1.61
- -
Dividend per Share
0.47
0.18
0.64
0.63
1.36
0.31
0.35
1.27
0.81
- -
Book Value per Share
11
11.49
13.55
13.33
13.29
15.61
13.69
14.63
14.12
14.87
Tangible Book Value per Share
10.95
11.45
13.52
13.32
13.29
15.61
13.69
14.63
14.12
14.87
Basic Weighted Avg Shares
37
38
43
44
43
47
48
51
57
58
Sales/Revenue/Turnover
534
573
676
808
725
677
734
744
779
- -
Operating Margin (%)
5.46
7.95
7.46
16.15
8.07
0.54
7.95
12.27
6.59
- -
Depreciation Expense
30
28
34
39
48
56
57
56
67
- -
Net Income, GAAP
21
37
36
101
39
14
40
89
54
- -
Effective Tax Rate (%)
21.22
25.87
26.92
24.54
37.98
20.62
26.11
17
24.17
- -
Profit Margin (%)
3.99
6.52
5.39
12.47
5.35
2.11
5.46
11.98
6.96
- -
Working Capital
186
188
206
216
126
221
200
376
273
218
LT Debt
5
5
36
100
70
108
45
124
135
127
Total Equity
420
438
517
580
578
650
664
804
823
853
Return on Invested Capital (%)
- -
7.2
6.79
14.03
4.16
0.32
4.87
7.97
3.56
- -
Return on Capital (%)
- -
8.11
7.05
15.01
4.84
2.03
5
9.89
5.5
- -
Return on Common Equity (%)
- -
8.71
7.63
18.36
6.7
2.32
6.1
12.15
6.67
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
194
213
338
LT Borrowings
159
133
123
LT Finance Leases
2
2
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
58
58
57
Market Capitalization
1,623
1,592
1,045

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
656
659
694
Cash, Cash Equivalents & STI
343
266
268
Accounts Receivable, Net
102
129
114
Inventories
159
179
207
Total Current Liabilities
309
386
476
Payables & Accruals
- -
- -
- -
ST Debt
194
213
338
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
7.55%
2.39%
Free Cash Flow
- -
-33.36%
-302.81%
Net Income, GAAP
- -
27.88%
-39.13%
Sales/Revenue/Turnover
- -
-0.48%
4.68%
Total Cash Common Dividend
- -
62.37%
-29.66%

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
744
2025
- -
- -
779
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.74
2025
- -
- -
0.95
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.27
2025
- -
- -
0.81
2026
- -
- -
- -

Company Description

CEO
Kuo-Chi Hsu
Full Time Employees
964
Sector
Health technology
Industry
Medical specialties
Address
No.100, Xingong 1st Road Changhua CHA Taiwan 521051
IPO Date
Mar 27, 2019
Business
Perfect Medical Industry Co., Ltd. manufactures and sells medical consumables and health supplies primarily for dialysis, infusion, and transfusion applications in Taiwan and internationally. The company offers hemodialysis blood tubing sets, A.V. fistula needle sets, Huber needle or winged needle sets, safety infusion sets, safety extension sets, blood transfusion sets, I.V. locks, disposable syringes, safety syringes, scalp vein sets, precision infusion sets, insulin syringes, blood collection devices, and medical face masks under its PF brand; it serves public and private clinics and hospitals across Asia, Africa, Europe, and South America while providing OEM and professional customization services. Founded in 1989 and headquartered in Beidou Township, Changhua County, Taiwan, with a manufacturing facility there employing about 80 staff and a larger plant in Vinh Loc Industrial Zone, Vietnam, employing around 840 workers, the company maintains ISO 13485:2016, CE, and QMS (GMP) certifications from Taiwan’s Ministry of Health and Welfare. It listed publicly on the Taipei Exchange's Emerging Stock Market under ticker 6543 in March 2019. In 2022, Perfect Medical expanded its product line to include protective consumables such as medical face masks, enhancing its global supply chain capabilities amid sustained production scaling through its Vietnam operations.